Filing Details

Accession Number:
0001181431-11-057709
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-28 16:27:45
Reporting Period:
2011-11-23
Filing Date:
2011-11-28
Accepted Time:
2011-11-28 16:27:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178711 Transcept Pharmaceuticals Inc TSPT Pharmaceutical Preparations (2834) 330960223
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1454280 P Thomas Soloway C/O Transcept Pharmaceuticals, Inc.
1003 W. Cutting Blvd, Suite 110
Point Richmond CA 94804
Svp, Operations And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-23 13,600 $2.68 13,600 No 4 M Direct
Common Stock Disposition 2011-11-23 13,600 $7.87 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee stock option (right to buy) Disposition 2011-11-23 13,600 $0.00 13,600 $2.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
63,900 2021-08-24 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,401 Indirect See footnote
Common Stock 20,833 Indirect See footnote
Footnotes
  1. Shares held directly by the Reporting Person has been reduced by 2,239 shares that were transferred on September 7, 2011 to the Thomas J. Soloway Revocable Family Trust for which the Reporting Person serves as trustee.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 13, 2011.
  3. The sales price reported in column 4 of Table 1 represents the weighted average sales price of the shares purchased ranging from $8.05 to $7.72 per share. Upon request of the commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  4. Shares held directly by the Thomas J. Soloway Revocable Family Trust ("the "Family Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein. The number of shares include 2,239 shares that were transferred on September 7, 2011 directly from the Reporting Person.
  5. Shares held directly by the Thomas J. Soloway 2003 Irrevocable Trust (the "2003 Trust") for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the 2003 Trust except to the extent of his pecuniary interet therein.
  6. Fifty percent of the option vests upon approval by the Federal Food and Drug Administration of Intermezzo (TM) and the remaining fifty percent vests on the first anniversary of any such approval; provided in each case, such approval occurs no later than August 24, 2013. Approval by the Federal Food and Drug Administration of Intermezzo (TM)occurred on November 23, 2011.